| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 11.56M | 53.78M | 30M | 1.54B | 88.03M | -10.7M | 4.49M | 0 |
| Revenue Growth % | - | 3.65% | -0.44% | 50.42% | -0.94% | -1.12% | 1.42% | -1% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 46.43M | 27.24M | 0 | 0 |
| COGS % of Revenue | - | - | - | - | 0.53% | -2.55% | - | - |
| Gross Profit | 11.56M | 53.78M | 30M | 1.54B | 41.59M | -248.8M | 4.49M | 0 |
| Gross Margin % | 1% | 1% | 1% | 1% | 0.47% | 23.26% | 1% | - |
| Gross Profit Growth % | - | 3.65% | -0.44% | 50.42% | -0.97% | -6.98% | 1.02% | -1% |
| Operating Expenses | 310.58M | 461.42M | 1.51B | 1.39B | 2.11B | 355.38M | 515.65M | 375.36M |
| OpEx % of Revenue | 26.88% | 8.58% | 50.32% | 0.9% | 24% | -33.22% | 114.95% | - |
| Selling, General & Admin | 25.44M | 66.39M | 654.55M | 402.41M | 899.94M | 199.88M | 63.91M | 216.46M |
| SG&A % of Revenue | 2.2% | 1.23% | 21.82% | 0.26% | 10.22% | -18.68% | 14.25% | - |
| Research & Development | 267.07M | 426.03M | 840.41M | 984.69M | 190.29M | 155.51M | 114.36M | 158.9M |
| R&D % of Revenue | 23.11% | 7.92% | 28.01% | 0.64% | 2.16% | -14.54% | 25.49% | - |
| Other Operating Expenses | 0 | 0 | 14.56M | 0 | 1.02B | -247 | 337.38M | 0 |
| Operating Income | -280.95M | -438.64M | -1.46B | 155.57M | -2.07B | -366.08M | -511.16M | -375.36M |
| Operating Margin % | -24.31% | -8.16% | -48.83% | 0.1% | -23.53% | 34.22% | -113.95% | - |
| Operating Income Growth % | - | -0.56% | -2.34% | 1.11% | -14.31% | 0.82% | -0.4% | 0.27% |
| EBITDA | -279.32M | -431.9M | -1.46B | 168.31M | -2.06B | -364.66M | -507.79M | -373.45M |
| EBITDA Margin % | -24.17% | -8.03% | -48.5% | 0.11% | -23.37% | 34.09% | -113.2% | - |
| EBITDA Growth % | - | -0.55% | -2.37% | 1.12% | -13.22% | 0.82% | -0.39% | 0.26% |
| D&A (Non-Cash Add-back) | 1.63M | 6.74M | 9.83M | 12.74M | 13.78M | 1.42M | 3.37M | 1.91M |
| EBIT | -44.82M | -56.61M | -207.09M | 155.57M | -2.07B | -52.65M | -347.62M | -375.36M |
| Net Interest Income | -732.92K | -1.03M | 3.94M | 3.56M | 21.33M | 4.95M | 7.2M | 54.64M |
| Interest Income | 131.42K | 668.26K | 4.37M | 3.71M | 21.33M | 4.95M | 7.3M | 54.64M |
| Interest Expense | 864.34K | 1.7M | 427.48K | 146.48K | 0 | 0 | 101.85K | 0 |
| Other Income/Expense | -17.29M | 37.53M | 13.02M | 327.58M | -260.73M | -607.09M | -954.53M | 12.63M |
| Pretax Income | -298.24M | -401.11M | -1.45B | 483.15M | -2.33B | -973.17M | -1.47B | -362.73M |
| Pretax Margin % | -25.81% | -7.46% | -48.4% | 0.31% | -26.49% | 90.97% | -326.74% | - |
| Income Tax | 0 | 1.72M | 0 | 12.23M | -494.81K | 697K | -1.26B | 0 |
| Effective Tax Rate % | 1% | 1% | 1.02% | 0.97% | 1% | 2.58% | 1% | 0.45% |
| Net Income | -298.24M | -402.83M | -1.49B | 470.92M | -2.33B | -2.51B | -1.47B | -162.26M |
| Net Margin % | -25.81% | -7.49% | -49.5% | 0.31% | -26.49% | 234.39% | -326.74% | - |
| Net Income Growth % | - | -0.35% | -2.69% | 1.32% | -5.95% | -0.08% | 0.42% | 0.89% |
| Net Income (Continuing) | -45.68M | -58.56M | -207.52M | 470.92M | -2.33B | -2.51B | -206.77M | -362.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200.47M |
| Minority Interest | 305.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.13 | -6.92 | -25.53 | 6.90 | -30.68 | -30.38 | -17.62 | -4.46 |
| EPS Growth % | - | -0.35% | -2.69% | 1.27% | -5.45% | 0.01% | 0.42% | 0.75% |
| EPS (Basic) | -5.13 | -6.92 | -25.53 | 8.07 | -30.70 | -30.38 | -17.62 | -4.46 |
| Diluted Shares Outstanding | 58.17M | 58.17M | 58.17M | 68.36M | 75.96M | 82.52M | 83.23M | 81.19M |
| Basic Shares Outstanding | 58.17M | 58.17M | 58.17M | 68.25M | 75.93M | 82.52M | 83.19M | 81.19M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 691.59M | 2.04B | 1.36B | 5.34B | 4.78B | 3.63B | 2.34B | 176.69M |
| Cash & Short-Term Investments | 574.17M | 1.84B | 1.17B | 733.21M | 670.96M | 3.45B | 2.29B | 173.4M |
| Cash Only | 307.93M | 1.59B | 1.14B | 4.76B | 3.52B | 3.21B | 2.14B | 68.26M |
| Short-Term Investments | 266.25M | 255.96M | 32M | 31.53M | 753.16M | 235.43M | 20.22M | 105.14M |
| Accounts Receivable | 628.15K | 9.36M | 7.99M | 71.31M | 60.95M | 4.81M | 1.83M | 1.17M |
| Days Sales Outstanding | 19.84 | 63.55 | 97.15 | 16.87 | 252.74 | -164.17 | 149.15 | - |
| Inventory | 0 | -215.57M | -55.87M | 0 | 4.27M | -80.28M | 28.95M | 0 |
| Days Inventory Outstanding | - | - | - | - | 33.59 | - | - | - |
| Other Current Assets | 114.86M | 218.85M | 238.85M | 4.53B | 4.03B | 242.96M | 15.68M | 0 |
| Total Non-Current Assets | 333.75M | 339.08M | 376.25M | 990.13M | 847.71M | 447.19M | 276.3M | 35.99M |
| Property, Plant & Equipment | 22.34M | 27.66M | 46.5M | 40.27M | 158.5M | 123.97M | 5.55M | 3.8M |
| Fixed Asset Turnover | 0.52x | 1.94x | 0.65x | 38.31x | 0.56x | -0.09x | 0.81x | - |
| Goodwill | 162.57M | 162.57M | 162.57M | 162.57M | 162.57M | 162.57M | 0 | 0 |
| Intangible Assets | 148.84M | 148.84M | 148.84M | 120.44M | 119.67M | 118.89M | 16.66M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 664.83M | 380.34M | 30.85M | 1.69M | 30.82M |
| Other Non-Current Assets | 0 | 0 | 18.33M | 2.01M | 26.63M | 10.91M | 252.39M | 1.36M |
| Total Assets | 1.03B | 2.38B | 1.74B | 6.33B | 5.63B | 4.07B | 2.61B | 212.68M |
| Asset Turnover | 0.01x | 0.02x | 0.02x | 0.24x | 0.02x | -0.00x | 0.00x | - |
| Asset Growth % | - | 1.32% | -0.27% | 2.65% | -0.11% | -0.28% | -0.36% | -0.92% |
| Total Current Liabilities | 195.14M | 346.16M | 588.48M | 576.13M | 624M | 659.74M | 411.81M | 8.45M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - |
| Short-Term Debt | 99M | 80M | 50M | -34.8M | 0 | 2.75M | 29.97M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 106K |
| Other Current Liabilities | 67.33M | 195.74M | 281.28M | 507.51M | -3.45M | 549.85M | -1.12M | 0 |
| Current Ratio | 3.54x | 5.88x | 2.31x | 9.28x | 7.66x | 5.50x | 5.67x | 20.90x |
| Quick Ratio | 3.54x | 6.51x | 2.41x | 9.28x | 7.66x | 5.62x | 5.60x | 20.90x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.13B | 2.98B | 3.18B | 130.52M | 417.63M | 405.6M | 483M | 3.07M |
| Long-Term Debt | 114.01M | 67.03M | 68.2M | 5.54M | 112.45M | 0 | 58.91M | 0 |
| Capital Lease Obligations | 0 | 0 | 7.49M | 5.54M | 81.79M | 32.07M | 23.1M | 3.07M |
| Deferred Tax Liabilities | 0 | 0 | 0 | -8.97M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.02B | 2.92B | 3.11B | 119.44M | -610K | 373.53M | 400.99M | 520 |
| Total Liabilities | 1.33B | 3.33B | 3.77B | 706.65M | 1.04B | 1.07B | 894.81M | 11.52M |
| Total Debt | 213.01M | 147.03M | 132.5M | 13.6M | 112.45M | 38.29M | 133.87M | 3.88M |
| Net Debt | -94.92M | -1.44B | -1B | -4.75B | -3.41B | -3.18B | -2.01B | -64.38M |
| Debt / Equity | 36.02x | - | - | 0.00x | 0.02x | 0.01x | 0.08x | 0.02x |
| Debt / EBITDA | - | - | - | 0.08x | - | - | - | - |
| Net Debt / EBITDA | - | - | - | -28.19x | - | - | - | - |
| Interest Coverage | -325.05x | -258.01x | -3426.98x | 1062.06x | - | - | -5018.58x | - |
| Total Equity | 5.91M | -955.1M | -2.03B | 5.63B | 4.59B | 3.01B | 1.72B | 201.16M |
| Equity Growth % | - | -162.53% | -1.13% | 3.77% | -0.18% | -0.34% | -0.43% | -0.88% |
| Book Value per Share | 0.10 | -16.42 | -34.98 | 82.31 | 60.40 | 36.46 | 20.64 | 2.48 |
| Total Shareholders' Equity | -299.8M | -955.1M | -2.03B | 5.63B | 4.59B | 3.01B | 1.72B | 201.16M |
| Common Stock | 6K | 6K | 6K | 114K | 126K | 132K | 18.76K | 19K |
| Retained Earnings | -357.86M | -1.01B | -2.49B | -2.02B | -4.35B | -6.77B | -8.33B | -1.29B |
| Treasury Stock | -1K | -1K | 0 | 0 | 0 | -21.25M | -56.8M | -6.22M |
| Accumulated OCI | 5.69M | 59.38M | 70.13M | -50.79M | -186.51M | 216.72M | 39.77M | 33.38M |
| Minority Interest | 305.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -252.16M | -280.7M | -867.98M | 433.56M | -973.09M | -1.1B | -72.85M | -52.65M |
| Operating CF Margin % | -21.82% | -5.22% | -28.93% | 0.28% | -11.05% | 103.09% | -16.24% | - |
| Operating CF Growth % | - | -0.11% | -2.09% | 1.5% | -3.24% | -0.13% | 0.93% | 0.28% |
| Net Income | -298.24M | -402.83M | -1.45B | 470.92M | -2.33B | -2.51B | -208.18M | -49.7M |
| Depreciation & Amortization | 1.63M | 6.74M | 15.63M | 23.14M | 34.14M | 63.82M | 1.06M | 978K |
| Stock-Based Compensation | 7.04M | 3.52M | 366.89M | 493.46M | 608.61M | 357.15M | 10.26M | -1.95M |
| Deferred Taxes | 8.53M | -75.03M | -6.39M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.83M | 38.97M | 23.04M | -313.31M | 321.18M | 431.48M | 161.2M | 809K |
| Working Capital Changes | 25.04M | 147.93M | 184.79M | -240.64M | 394.52M | 552.06M | -37.2M | -2.81M |
| Change in Receivables | 0 | -11M | 11M | -130.5M | 97.42M | 33.08M | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | -27.24M | 27.24M | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 107.85M | 0 | 0 | 0 |
| Cash from Investing | -157.66M | 9.5M | 212.46M | -201.9M | -727.21M | 458.38M | -107.63M | -135.97M |
| Capital Expenditures | -20.33M | -14.41M | -12.24M | -8.01M | -29.93M | -45.83M | -164.35K | -48K |
| CapEx % of Revenue | 1.76% | 0.27% | 0.41% | 0.01% | 0.34% | -4.28% | 0.04% | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -230.67M | 23.91M | 224.7M | 52M | 0 | 26K | -107.47M | 62K |
| Cash from Financing | 758.59M | 1.48B | 152.71M | 3.44B | 593.92M | 42.36M | -8.25M | -334.89K |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | -5.28M | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 594.2M | 1.23B | 131.76M | 2.91B | 593.92M | 60.86M | 407.88K | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -272.48M | -295.11M | -880.22M | 425.55M | -1B | -1.15B | -73.02M | -52.72M |
| FCF Margin % | -23.58% | -5.49% | -29.34% | 0.28% | -11.39% | 107.38% | -16.28% | - |
| FCF Growth % | - | -0.08% | -1.98% | 1.48% | -3.36% | -0.15% | 0.94% | 0.28% |
| FCF per Share | -4.68 | -5.07 | -15.13 | 6.22 | -13.20 | -13.92 | -0.88 | -0.65 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.70x | 0.58x | 0.92x | 0.42x | 0.44x | 0.05x | 0.32x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 710.39K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 1.42M | 103K | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -5043.8% | - | - | 26.22% | -45.65% | -66.02% | -62.02% | -16.91% |
| Return on Invested Capital (ROIC) | - | - | - | 13.23% | -150.93% | -54.41% | - | - |
| Gross Margin | 100% | 100% | 100% | 100% | 47.25% | 2325.83% | 100% | - |
| Net Margin | -2580.82% | -749.02% | -4950% | 30.53% | -2648.7% | 23438.9% | -32674.02% | - |
| Debt / Equity | 36.02x | - | - | 0.00x | 0.02x | 0.01x | 0.08x | 0.02x |
| Interest Coverage | -325.05x | -258.01x | -3426.98x | 1062.06x | - | - | -5018.58x | - |
| FCF Conversion | 0.85x | 0.70x | 0.58x | 0.92x | 0.42x | 0.44x | 0.05x | 0.32x |
| Revenue Growth | - | 365.39% | -44.22% | 5042.23% | -94.29% | -112.15% | 141.93% | -100% |
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Licensing and Collaboration | - | 40.12M | -249.66M | 16.81M |
| Licensing and Collaboration Growth | - | - | -722.37% | 106.73% |
| Supply Of Investigational Products | - | 47.91M | 28.1M | 10.83M |
| Supply Of Investigational Products Growth | - | - | -41.35% | -61.46% |
| Grant | 10M | - | - | - |
| Grant Growth | - | - | - | - |
NovaBridge Biosciences (NBP) saw revenue decline by 100.0% over the past year.
NovaBridge Biosciences (NBP) reported a net loss of $24.5M for fiscal year 2024.
NovaBridge Biosciences (NBP) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
NovaBridge Biosciences (NBP) generated $1.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.